BRAF and melanoma: As dabrafenib and vemurafenib have different potencies against mutant BRAF in isolated kinase assays, we determined equipotent concentrations of drug required to inhibit pERK in 1205Lu BRAF‐mutant melanoma cells (Bollag et al., 2010; King et al., 2013) and identified 100 nm dabrafenib to have equivalent effects to 1 μm of vemurafenib (Fig. S1).